|Day Low/High||4.89 / 5.14|
|52 Wk Low/High||1.41 / 8.61|
Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Proteostasis Therapeutics, Inc.
Designation granted for PTI-428 for the treatment of CF patients based on the results from a recent Phase 2, randomized, placebo controlled study
Triple Combination of PTI-428, PTI-801 and PTI-808 Study to Initiate Dosing in CF Patients in 1H'18
Company to Host Conference Call and Webcast Today at 5:00 p.m. ET
Screening Initiated in Phase 2 Portion of PTI-428 Study, 28-day Dosing Cohort
Updates Announced During the 40th European Cystic Fibrosis Society Conference
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.